Germany’s 2026 AMNOG reform (GKV-BStabG) marks a significant shift in the pharmaceutical pricing, reimbursement and market access landscape. But its impact will not be the same for every product.
Launch timing, sales potential, lifecycle stage, benefit rating, and exposure to regional payer contracting could all influence how individual products and broader portfolios are affected. Understanding these implications will be critical for both immediate decision-making and longer-term pricing and reimbursement strategy.
Join our experts as they unpack the new AMNOG landscape, what it means for pharma companies, and the strategic implications teams should consider.
This webinar will cover:
- Key changes to the German AMNOG pricing and reimbursement framework, including the repeal of guardrails and stricter price-volume agreements
- The new 8.5% manufacturer rebate and potential pathways for exemption
- The introduction of rebate contracting for specific patented product classes
- Implications for portfolio strategy and P&R planning, including launch timing and price (re-)negotiations
- Actions to consider for affected in-market products and future launches
This webinar is free of charge. Don’t miss the opportunity to gain insights into what the new AMNOG landscape means for your strategy.
